Skip to main navigation Skip to search Skip to main content

Targeting aurora kinases in cancer treatment

  • Kevin R. Kelly
  • , Jeffrey Ecsedy
  • , Devalingam Mahalingam
  • , Steffan T. Nawrocki
  • , Swaminathan Padmanabhan
  • , Francis J. Giles
  • , Jennifer S. Carew
  • Institute for Drug Development
  • Millennium Pharmaceuticals, Inc.

Research output: Contribution to a Journal (Peer & Non Peer)Review articlepeer-review

42 Citations (Scopus)

Abstract

The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition. Moreover, early phase clinical studies have shown that these agents have therapeutic efficacy. In this review, we will outline the functions of Aurora kinases in normal cell division and in malignancy. We will focus on recent preclinical and clinical studies that have explored the mechanism of action and clinical effect of Aurora inhibitors in cancer treatment.

Original languageEnglish
Pages (from-to)2067-2078
Number of pages12
JournalCurrent Drug Targets
Volume12
Issue number14
DOIs
Publication statusPublished - Dec 2011
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Aurora kinase inhibitors
  • Cancer
  • Mitosis
  • Targeted therapy

Fingerprint

Dive into the research topics of 'Targeting aurora kinases in cancer treatment'. Together they form a unique fingerprint.

Cite this